Childhood Idiopathic Nephrotic Syndrome
Stories
-
Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome
The study, completed in September 2025, enrolled 85 participants aged 2-25 years and compared obinutuzumab with mycophenolate mofetil. Results were first posted on ClinicalTrials.gov on October 14, 2026.